- 米国企業
- Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.AUPH
時価総額
$8.3億
PER
2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
Product | - | 45 | 103 | 159 |
License | 50 | 0 | 31 | - |
License, collaboration and royalty revenue | - | - | - | 17 |
Total revenue, net | 50 | 46 | 134 | 176 |
Cost of sales | - | 1 | 6 | 14 |
General and Administrative Expense | 96 | 171 | 196 | 195 |
Research and development | 50 | 51 | 45 | 50 |
Other expense (income), net | 7 | -1 | 2 | -8 |
Total cost of sales and operating expenses | - | 226 | 246 | 267 |
Loss from operations | -104 | -181 | -111 | -92 |
Interest income | - | - | 5 | 17 |
Interest expense | - | - | - | 3 |
Net loss before income taxes | -103 | -180 | -106 | -77 |
Interest income | - | - | 5 | 17 |
Income tax expense | -0 | 1 | 2 | 1 |
Net loss before income taxes | -103 | -180 | -106 | -77 |
Net loss | -103 | -181 | -108 | -78 |
Income tax expense | -0 | 1 | 2 | 1 |
Unrealized gain (loss) on available-for-sale securities, net of tax of nil | - | -0 | -0 | 0 |
Net loss | -103 | -181 | -108 | -78 |
Comprehensive loss | - | -181 | -108 | -78 |
Unrealized gain (loss) on available-for-sale securities, net of tax of nil | - | -0 | -0 | 0 |
Earnings Per Share, Basic | - | -1.4 | -0.76 | -0.54 |
Comprehensive loss | - | -181 | -108 | -78 |
Earnings Per Share, Diluted | - | -1.4 | -0.76 | -0.54 |
Earnings Per Share, Basic | - | -1.4 | -0.76 | -0.54 |
Earnings Per Share, Diluted | - | -1.4 | -0.76 | -0.54 |